

1 **Elevated renin activity and change in sleep apnea with primary** 2 **aldosteronism**

3
4 Yonekazu Kidawara, M.D., Ph.D.¹ Manabu Kadoya, M.D., Ph.D.¹ Masataka Igeta,
5 Ph.D.² Miki Kakutani-Hatayama, M.D., Ph.D.¹ Akiko Morimoto, M.D., Ph.D.¹ Akio
6 Miyoshi, M.D., Ph.D.¹ Akinori Kanzaki, M.D., Ph.D.¹ Kosuke Konishi, M.D.,
7 Ph.D.¹ Takashi Daimon, Ph.D.² and Hidenori Koyama M.D., Ph.D.¹

8
9 ¹Department of Diabetes, Endocrinology and Clinical Immunology, School of
10 Medicine, Hyogo Medical University, Nishinomiya, Hyogo, Japan

11 ²Department of Biostatistics, School of Medicine, Hyogo Medical University,
12 Nishinomiya, Hyogo, Japan

13
14 **Short title:** Primary aldosteronism and sleep apnea

15 16 **Corresponding author:**

17 Manabu Kadoya, M.D., Ph.D.

18 Department of Diabetes, Endocrinology and Clinical Immunology, School of
19 Medicine, Hyogo Medical University

20 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan

21 Tel: +81 798 45 6473; Fax: +81 798 45 6443

22 Email: mkadoya@hyo-med.ac.jp

23 **ORCID:** 0009-0004-3541-5270

24
25 Total words (excluding abstract and references): 2301

33 **ABSTRACT**

34 **Background:** The prevalence of obstructive sleep apnea (OSA) is higher in
35 patients with primary aldosteronism (PA), while elevated renin activity after
36 treatment is associated with a lower risk of cardiovascular events. However, the
37 association of PA with degree of OSA remains unclear and it is not known
38 whether elevated renin activity in PA patients is associated with change in apnea
39 condition.

40 **Methods:** Cross-sectional relationships between PA (n=176) and degree of OSA
41 classified by apnea-hypopnea index (AHI) with use of an apnomonitor were
42 investigated, with the results compared with those obtained with non-PA patients
43 (n=418). Additionally, the effects of elevated renin activity on change in AHI were
44 prospectively examined in 45 patients with PA.

45 **Results:** Patients with PA were found to be significantly associated with severe
46 OSA even after adjustment for other clinical risk factors (odds ratio 2.08, 95%
47 confidence interval 1.09-3.95, $p = 0.025$) as compared to those without PA.
48 Furthermore, the logarithm of the renin activity after treatment and change in AHI
49 before and after treatment were significantly negatively correlated, with
50 Pearson's correlation coefficient ($r = -0.364$, $p = 0.014$).

51 **Conclusions:** Severe OSA is more commonly seen in PA patients with
52 hypertension as compared to patients without PA, and elevated renin activity
53 may contribute to improvement of sleep apnea in patients with PA.

54

55 **Keywords:** primary aldosteronism, sleep apnea, AHI, renin activity

56

57 **Introduction**

58 Primary aldosteronism (PA) is recognized as one of the most common causes of
59 secondary hypertension, and affected individuals have also been shown to have
60 a higher risk for cardiovascular events and mortality independent of blood
61 pressure level as compared to patients with essential hypertension (EH)¹⁻⁴.
62 Obstructive sleep apnea (OSA), another well-known cause of hypertension, has
63 also been found to contribute to increased risk of cardiovascular morbidity and
64 mortality⁵⁻⁷. In patients with PA, the prevalence of OSA has been reported to be
65 as high as 60% to 80%⁸. Additionally, those patients have a tendency for higher
66 OSA prevalence as compared to patients without PA who are hypertension
67 resistant⁹. Another report regarding risk of PA showed that individuals with
68 maintained suppression of renin activity had increased risk of cardiovascular
69 events and death¹⁰. Therefore, unsuppressed renin activity is now recognized
70 as a therapeutic goal for PA patients, though it remains unclear whether elevated
71 renin activity is associated with changes related to apnea. The present study
72 was performed as a cross-sectional examination of the association of PA with

73 degree of OSA and also prospectively investigated the effect of elevated renin

74 activity on sleep apnea.

75

76 **Methods**

77 **Study design and participants**

78 From October 2010 to November 2020, 1151 patients assessed for diagnosis of

79 PA and OSA were enrolled in the Hyogo Sleep Cardio-Autonomic

80 Atherosclerosis (HSCAA) study. Out of these, 781 were hypertensive patients

81 including those with PA. For the present study, those with autonomous cortisol

82 secretion, pheochromocytoma, primary hyperparathyroidism, estimated

83 glomerular filtration rate (eGFR) <15 mL/min/1.73 m², or dialysis treatment were

84 excluded (n=128). Additionally, 59 with missing baseline data regarding

85 assessment of OSA were also excluded. Finally, 594 were enrolled, and divided

86 into the PA (n=176) and non-PA (n=418) groups. Of those with PA, 45 patients

87 were simultaneously reassessment for renin activity and sleep apnea within five

88 years (**Figure 1**). HSCAA study, which has received approved by the institutional

89 ethical committee of Hyogo Medical University (approval No. 2351), was used

90 and informed written consent was obtained from each participant.

91

92 **Plasma biochemical parameters**

93 Blood samples were obtained in the morning after an overnight fast and then

94 quickly centrifuged to obtain plasma. Whole blood was used for hemoglobin A1c,

95 EDTA plasma for glucose and lipids, and serum for other biochemical assays.

96 Glucose measurements were performed using a glucose oxidase method and

97 an enzymatic method was used to determine serum creatinine concentration.

98 Estimated glomerular filtration rate in each patient was calculated using an

99 equation for Japanese subjects, as follows: estimated glomerular filtration rate

100 $(\text{mL}/\text{min per } 1.73 \text{ m}^2) = 194 \times \text{age (years)}^{-0.287} \times \text{S-creatinine}^{-1.094}$ (if female, $\times 0.739$).

101 Plasma renin activity (PRA) and plasma aldosterone concentration (PAC) were

102 measured using an enzyme immunoassay with the patient at rest in a supine

103 position for 30 minutes.

104

105 **Diagnosis of primary aldosteronism**

106 Patients were diagnosed with PA based on a PAC (pg/mL) to PRA (ng/mL/hour)

107 ratio (ARR) ≥ 200 at screening and at least one positive result from confirmatory

108 tests for PA diagnosis (saline infusion test, captopril challenge test,

109 furosemide-upright test) at the time of admission, according to previously

110 reported guidelines^{11,12}.

111

112 **Assessment of sleep apnea**

113 To determine the presence of sleep apnea, an apnomonitor device (SAS-2100,

114 Nihon Kohden, Tokyo, Japan; supplied by Teijin, Tokyo, Japan) was used to

115 provide apnea-hypopnea index (AHI) values. Criteria presented in The American

116 Academy of Sleep Medicine Manual for the Scoring of Sleep and Associated

117 Events, version 2.1, were used for analysis of respiratory events, as follows.

118 Apnea was defined when the amplitude ratio to normal breathing was $\leq 10\%$ with

119 air flow lasting ≥ 10 seconds, and hypopnea when the amplitude ratio to normal

120 breathing was $\leq 70\%$ with air flow lasting ≥ 10 seconds and associated with a 4%

121 decrease in oxygen saturation. AHI was calculated as the average number of

122 apnea and hypopnea episodes per hour. When the decrease was 3% or more

123 per second or the sensor was disconnected, the result was considered an

124 artifact and excluded from analysis. The degree of sleep apnea was classified

125 based on AHI values as none (0 to <5), mild (5 to <15), moderate (15 to <30), or

126 severe (≥ 30)¹³.

127

128 **Statistical analyses**

129 For comparisons of mean and median values of continuous variables for the
130 baseline clinical characteristics between PA status (PA and non-PA), and also
131 suppressed renin activity status in patients with PA (remained suppressed and
132 unsuppressed), Welch's t-test or the Mann-Whitney U-test was used. Fisher's
133 exact test was used for categorical variables. Multivariable logistic regression
134 analysis was used to calculate odds ratio (OR) and 95% confidence interval (CI)
135 values for the associations of degree of OSA with PA as compared to the non-PA
136 group adjusting for clinical factors, including potential causal factors for sleep
137 apnea, i.e., age, male gender, BMI, systolic BP, HbA1c, and renal function. In
138 addition, a Pearson's correlation coefficient was calculated to evaluate the
139 association between the change of AHI and elevation of the renin activity in PA
140 patients. The logarithmic transformation was performed to the renin activity for a
141 normal approximation. All statistical analyses were performed with EZR, version
142 1.61 (Saitama Medical Center, Jichi Medical University, Saitama, Japan) and
143 SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA). All reported P
144 values are two-sided and considered to be statistically significant at <0.05

145 without adjustment for multiplicity.

146

147 **Results**

148 **Baseline clinical characteristics**

149 The baseline characteristics of the present patients after dividing into the PA and
150 non-PA groups are shown in **Table 1**. The distribution of degree of sleep apnea
151 in those with PA was as follows: normal (AHI <5), 26.7%; mild (AHI 5 to <15),
152 38.6%; moderate (AHI 15 to <30), 18.8%; and severe (AHI ≥30), 15.9%. Patients
153 with PA exhibited higher levels of systolic BP, diastolic BP, and plasma
154 aldosterone concentration, lower levels of fasting plasma glucose, HbA1c, and
155 plasma renin activity, and lower prevalence of diabetes and dyslipidemia, as
156 compared to the non-PA group.

157

158 The baseline clinical characteristics of the patients classified by degree of OSA
159 are presented in **Table 2**. Comparisons were also made between patients
160 classified according to degree of OSA and those without OSA. There were no
161 clinically significant differences in regard to smoking, diastolic BP,
162 LDL-cholesterol, PRA, PAC, or use of anti-hypertensive drugs such as

163 calcium-channel blocker and diuretic agent between patients with OSA
164 regardless of severity as compared to those without OSA. Patients with OSA
165 showed higher levels of BMI, systolic BP, FPG, and HbA1c, and a higher
166 prevalence for male gender and diabetes, and lower level of eGFR as compared
167 to patients without OSA. Those with mild or moderate OSA were older than
168 those without OSA. As compared to patients without OSA, those with moderate
169 or severe OSA had lower levels of HDL, higher levels of TG, and a higher
170 prevalence of dyslipidemia. Users of α blocker anti-hypertensive drugs were
171 more frequently noted among patients with severe OSA as compared to those
172 without OSA. Furthermore, the prevalence of PA tended to be higher in patients
173 with severe OSA, though the difference was not significant as compared to
174 patients classified with other levels of OSA.

175

176 **Relationship of PA with degree of OSA**

177 Results of multivariable logistic analysis performed to examine the associations
178 of PA with each level of OSA as compared to non-PA patients are shown in **Table**
179 **3**. This analysis was fully adjusted for clinical factors, including potential causal
180 factors for sleep apnea, i.e., age, male gender, BMI, systolic BP, HbA1c, and

181 renal function. PA was shown to have a significant association with only severe
182 OSA. These results suggest that patients with PA are more likely than
183 hypertensive patients without PA to be complicated by severe sleep apnea under
184 adjustment of the potential causal factors for sleep apnea.

185

186 **Effects of elevated renin activity on change of sleep apnea**

187 Renin activity and AHI were reevaluated after a mean of 2.5 ± 1.6 years in 45 PA
188 patients. Pearson's correlation coefficient were used to evaluate the association
189 between the logarithm of the renin activity at reevaluation and amount of change
190 in AHI, as shown in **Figure 2**. This relationship was significantly negatively
191 correlated ($r = -0.364$, $p = 0.014$).

192

193 **Discussion**

194 This is the first study to assess cross-sectional associations among PA patients
195 with various degrees of OSA. Moreover, the effects of remaining suppressed
196 renin activity on sleep apnea in patients with PA were prospectively examined.
197 PA was found to be strongly associated with severe sleep apnea under
198 adjustment of the potential causal factors for sleep apnea. Additionally, they

199 show that elevated renin activity can potentially prevent the progression of sleep
200 apnea in patients with PA.

201

202 Epidemiological studies have found that PA is a disease that can cause sleep
203 apnea. Among patients with resistant hypertension, the degree of OSA has been

204 reported to be higher in those with hyperaldosteronism ¹⁴. The present results

205 show an association of PA with severe sleep apnea under adjustment of the

206 potential causal factors for sleep apnea. Previously, it was suggested that

207 excessive aldosterone secretion causes inappropriate sodium and fluid retention

208 ⁶. Furthermore, mechanisms related to fluid movement from the lower

209 extremities to the neck caused by edema of the upper airway may contribute to

210 the etiology of OSA ¹⁵. Another study noted that patients with OSA who

211 underwent diuretic treatment showed significantly improved upper airway caliber

212 and OSA, further implicating pharyngeal edema as a cause of upper airway

213 collapse during sleep ¹⁶. Moreover, a volumetric analysis technique used with

214 magnetic resonance imaging demonstrated that volume of the tongue and lateral

215 walls were independent factors related to increased risk of OSA ¹⁷. Impairment of

216 ventilatory-control mechanisms can also contribute to modulation of pharyngeal

217 collapsibility during sleep, thus suggesting a role for central nervous system
218 input, which may be influenced by humoral factors ¹⁸⁻²⁰. Furthermore, basic
219 research results have indicated that aldosterone has a central role in increased
220 brain renin-angiotensin activity, oxidative stress, and sympathetic drive ²¹.
221 Therefore, in addition to pharyngeal edema caused by inappropriate sodium and
222 fluid retention related to hyperaldosteronism, disruptions in normal central
223 respiratory mechanisms by aldosterone-induced activation of central receptors
224 may potentially contribute to the association between PA and sleep apnea
225 severity.

226

227 Aldosterone receptor antagonists are used as therapeutic agents in patients with
228 PA. Such medication has also been indicated as effective for not only improving
229 hypertension but also preventing complications, including cardiovascular events.
230 Spironolactone treatment for patients with resistant hypertension has been
231 reported to significantly decrease AHI level ²². As for pharmacological treatment
232 for PA, elevated renin activity has been shown useful to prevent development of
233 cardiovascular events, cardiovascular death, and renal dysfunction, thus
234 elevated renin activity is considered to be a therapeutic goal. A possible

235 mechanism underlying the association between elevated renin activity and sleep
236 apnea following therapeutic intervention may be inhibition of mineralocorticoid
237 receptor activation by aldosterone antagonists or an adrenalectomy for
238 aldosterone-producing adenoma treatment²³. Elevated renin activity is used as
239 an indicator of suppressed mineralocorticoid receptor activation. Results of the
240 present study indicate that elevated renin activity leads to prevent progress of
241 sleep apnea.

242

243 This study has several limitations. First, the findings may not be generalizable to
244 all patients with different blood pressure status. Second, the present cohort did
245 not take into account the effect of change in body weight, as that was not
246 possible to track. Nevertheless, the present findings are considered to provide
247 important initial information for clarification of the association of PA with sleep
248 apnea. Moreover, there was a significant negative correlation between the renin
249 activity after treatment and change in AHI before and after treatment. The results
250 suggest that the increase in renin activity reflects suppression of aldosterone
251 action, which may lead to improvement of sleep apnea via improvement of
252 pharyngeal edema.

253

254 **Conclusion**

255 As compared to hypertensive patients without PA, patients with PA are more
256 likely to have severe sleep apnea. Furthermore, elevated renin activity may
257 contribute to improvement of sleep apnea in patients with PA.

258

259 **Perspectives**

260 PA appears to play a fundamental role in development of sleep apnea. The
261 elevated renin activity is used as an indicator of the effects of PA treatment goals
262 as well as need for prevention of various complications. The present study
263 investigated the association of PA with degree of OSA as compared to non-PA
264 patients with hypertension and is the first to report a relationship between
265 elevated renin activity and changes in sleep apnea in PA patients. The results
266 provide important initial insight regarding the association of PA with degree of
267 sleep apnea as well as for determining whether elevated renin activity has
268 effects on sleep apnea in patients with PA.

269

270 **Acknowledgements**

271 The authors are grateful for the excellent technical assistance provided by
272 Tomoe Ushitani and Ai Matsumoto. We also wish to thank the other investigators
273 and staff members, as well as the participants of the HSCAA study for their
274 valuable contributions.

275

276 **Funding**

277 JSPS KAKENHI grants (24K19043 to Y. Kidawara, 20K18944 to A. Mrimoto) and
278 Hyogo Medical University (Hyogo Innovative Challenge to H. Koyama) were
279 received.

280

281 **Disclosures**

282 There no conflicts of interest or commercial affiliations to disclose.

283

284 **Data Availability**

285 The datasets generated during and/or analyzed for the current study are not
286 publicly available, though can be provided by the corresponding author upon
287 reasonable request.

288

289 **Novelty and Relevance**

290 **What is new?**

291 This study sheds light on the currently incompletely understood association
292 between PA and degree of OSA in hypertensive patients and effect of elevated
293 renin activity for change in sleep apnea in patients with PA. An increased risk of
294 severe OSA is revealed in patients with PA. Furthermore, it indicated that
295 elevated renin activity following treatment can possible to prevent sleep apnea
296 progression.

297 **What Is Relevant?**

298 Our results provide important initial findings to unveil the pathophysiological
299 factors for PA and OSA.

300 **Clinical/Pathophysiological Implications?**

301 PA is an important risk factor for severe OSA in hypertensive patients, and
302 elevated renin activity following treatment is negatively correlated with
303 progression of sleep apnea. These knowledge could improve the prediction and
304 progression of sleep apnea in patients with PA.

305

306 **References**

- 307 1. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence
308 for an increased rate of cardiovascular events in patients with primary
309 aldosteronism. *J Am Coll Cardiol.* 2005;45:1243-1248. doi:
310 10.1016/j.jacc.2005.01.015

- 311 2. Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T. Vascular
312 complications in patients with aldosterone producing adenoma in Japan:
313 comparative study with essential hypertension. The Research Committee
314 of Disorders of Adrenal Hormones in Japan. *J Endocrinol Invest.*
315 1995;18:370-373. doi: 10.1007/BF03347840
- 316 3. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi
317 LA. Cardiovascular outcomes in patients with primary aldosteronism after
318 treatment. *Arch Intern Med.* 2008;168:80-85. doi:
319 10.1001/archinternmed.2007.33
- 320 4. Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications
321 associated with primary aldosteronism: a controlled cross-sectional study.
322 *Hypertension.* 2013;62:331-336. doi:
323 10.1161/HYPERTENSIONAHA.113.01060
- 324 5. Shah NA, Yaggi HK, Concato J, Mohsenin V. Obstructive sleep apnea as
325 a risk factor for coronary events or cardiovascular death. *Sleep Breath.*
326 2010;14:131-136. doi: 10.1007/s11325-009-0298-7
- 327 6. Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A,
328 Daniels S, Floras JS, Hunt CE, Olson LJ, et al. Sleep apnea and

- 329 cardiovascular disease: an American Heart Association/American College
330 Of Cardiology Foundation Scientific Statement from the American Heart
331 Association Council for High Blood Pressure Research Professional
332 Education Committee, Council on Clinical Cardiology, Stroke Council, and
333 Council On Cardiovascular Nursing. In collaboration with the National
334 Heart, Lung, and Blood Institute National Center on Sleep Disorders
335 Research (National Institutes of Health). *Circulation*. 2008;118:1080-1111.
336 doi: 10.1161/CIRCULATIONAHA.107.189375
- 337 7. Wang X, Ouyang Y, Wang Z, Zhao G, Liu L, Bi Y. Obstructive sleep apnea
338 and risk of cardiovascular disease and all-cause mortality: a
339 meta-analysis of prospective cohort studies. *Int J Cardiol*.
340 2013;169:207-214. doi: 10.1016/j.ijcard.2013.08.088
- 341 8. Florczak E, Prejbisz A, Szwench-Pietrasz E, Sliwiński P, Bieleń P,
342 Klisiewicz A, Michałowska I, Warchoń E, Januszewicz M, Kała M, et al.
343 Clinical characteristics of patients with resistant hypertension: the
344 RESIST-POL study. *J Hum Hypertens*. 2013;27:678-685. doi:
345 10.1038/jhh.2013.32
- 346 9. Prejbisz A, Florczak E, Klisiewicz A, Dobrowolski P, Janaszek-Sitkowska

- 347 H, Bieleń P, Szwench-Pietrasz E, Warchoń-Celińska E,
348 Kołodziejczyk-Kruk S, Janas J, et al. Relationship between primary
349 aldosteronism and obstructive sleep apnoea, metabolic abnormalities and
350 cardiac structure in patients with resistant hypertension. *Endokrynol Pol.*
351 2013;64:363-367. doi: 10.5603/EP.2013.0019
- 352 10. Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A.
353 Cardiometabolic outcomes and mortality in medically treated primary
354 aldosteronism: a retrospective cohort study. *Lancet Diabetes Endocrinol.*
355 2018;6:51-59. doi: 10.1016/S2213-8587(17)30367-4
- 356 11. Naruse M, Katabami T, Shibata H, Sone M, Takahashi K, Tanabe A, Izawa
357 S, Ichijo T, Otsuki M, Omura M, et al. Japan Endocrine Society clinical
358 practice guideline for the diagnosis and management of primary
359 aldosteronism 2021. *Endocr J.* 2022;69:327-359. doi:
360 10.1507/endocrj.EJ21-0508
- 361 12. Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, Horio T,
362 Hoshida S, Ikeda S, Ishimitsu T, et al. The Japanese Society of
363 Hypertension Guidelines for the Management of Hypertension (JSH
364 2019). *Hypertens Res.* 2019;42:1235-1481. doi:

365 10.1038/s41440-019-0284-9

366 13. Kapur VK, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R, Ramar K,
367 Harrod CG. Clinical Practice Guideline for Diagnostic Testing for Adult
368 Obstructive Sleep Apnea: An American Academy of Sleep Medicine
369 Clinical Practice Guideline. *J Clin Sleep Med*. 2017;13:479-504. doi:
370 10.5664/jcsm.6506

371 14. Gonzaga CC, Gaddam KK, Ahmed MI, Pimenta E, Thomas SJ, Harding
372 SM, Oparil S, Cofield SS, Calhoun DA. Severity of obstructive sleep
373 apnea is related to aldosterone status in subjects with resistant
374 hypertension. *J Clin Sleep Med*. 2010;6:363-368.

375 15. Shiota S, Ryan CM, Chiu KL, Ruttanaumpawan P, Haight J, Arzt M,
376 Floras JS, Chan C, Bradley TD. Alterations in upper airway
377 cross-sectional area in response to lower body positive pressure in
378 healthy subjects. *Thorax*. 2007;62:868-872. doi:
379 10.1136/thx.2006.071183

380 16. Bucca CB, Brussino L, Battisti A, Mutani R, Rolla G, Mangiardi L, Cicolin
381 A. Diuretics in obstructive sleep apnea with diastolic heart failure. *Chest*.
382 2007;132:440-446. doi: 10.1378/chest.07-0311

- 383 17. Schwab RJ, Pasirstein M, Pierson R, Mackley A, Hachadoorian R, Arens
384 R, Maislin G, Pack AI. Identification of upper airway anatomic risk factors
385 for obstructive sleep apnea with volumetric magnetic resonance imaging.
386 *Am J Respir Crit Care Med.* 2003;168:522-530. doi:
387 10.1164/rccm.200208-866OC
- 388 18. Wolk R, Johnson BD, Somers VK. Leptin and the ventilatory response to
389 exercise in heart failure. *J Am Coll Cardiol.* 2003;42:1644-1649. doi:
390 10.1016/j.jacc.2003.06.007
- 391 19. Somers VK, Mark AL, Zavala DC, Abboud FM. Influence of ventilation and
392 hypocapnia on sympathetic nerve responses to hypoxia in normal
393 humans. *J Appl Physiol (1985).* 1989;67:2095-2100. doi:
394 10.1152/jappl.1989.67.5.2095
- 395 20. Somers VK, Mark AL, Zavala DC, Abboud FM. Contrasting effects of
396 hypoxia and hypercapnia on ventilation and sympathetic activity in
397 humans. *J Appl Physiol (1985).* 1989;67:2101-2106. doi:
398 10.1152/jappl.1989.67.5.2101
- 399 21. Zhang ZH, Yu Y, Kang YM, Wei SG, Felder RB. Aldosterone acts centrally
400 to increase brain renin-angiotensin system activity and oxidative stress in

401 normal rats. *Am J Physiol Heart Circ Physiol*. 2008;294:H1067-1074. doi:

402 10.1152/ajpheart.01131.2007

403 22. Yang L, Zhang H, Cai M, Zou Y, Jiang X, Song L, Liang E, Bian J, Wu H,

404 Hui R. Effect of spironolactone on patients with resistant hypertension

405 and obstructive sleep apnea. *Clin Exp Hypertens*. 2016;38:464-468. doi:

406 10.3109/10641963.2015.1131290

407 23. Valaiyapathi B, Calhoun DA. Role of Mineralocorticoid Receptors in

408 Obstructive Sleep Apnea and Metabolic Syndrome. *Curr Hypertens Rep*.

409 2018;20:23. doi: 10.1007/s11906-018-0819-5

410

411

412 **Figure legends**

413 **Figure 1. Flow of subject selection.**

414 eGFR, estimated glomerular filtration rate; PA, primary aldosteronism.

415

416 **Figure 2. Association between renin activity following treatment and**

417 **amount of changes in AHI.**

418 Correlation coefficient and p values for association between renin activity

419 following treatment and amount of change in AHI were calculated using a

420 Pearson's correlation coefficient.

421

Table 1. Comparisons of baseline clinical characteristics

Variables	PA	Non-PA	P
Number of patients	176	418	
Age, years	57.1 ± 12.8	63.7 ± 12.2	<0.001
Male, n (%)	84 (47.7)	231 (55.3)	0.112
Body mass index, kg/m ²	25.4 ± 4.9	25.3 ± 5.2	0.682
Current smoker, n (%)	41 (23.3)	113 (27.0)	0.397
Systolic BP, mmHg	137.2 ± 15.7	131.2 ± 14.4	<0.001
Diastolic BP, mmHg	82.4 ± 10.3	76.4 ± 9.0	<0.001
LDL cholesterol, mg/dL	112.6 ± 29.4	111.8 ± 32.5	0.818
HDL cholesterol, mg/dL	54.8 ± 15.9	53.1 ± 17.0	0.273
Triacylglycerol, mg/dL	120.5 (84.0 – 165.3)	115.0 (85.0 – 171.0)	0.911
eGFR, mL/min/1.73 m ²	80.0 ± 19.2	77.6 ± 23.0	0.224
Fasting plasma glucose, mg/dL	98 (91 - 106)	101 (93 - 121)	<0.001
HbA1c (%)	5.5 (5.2 - 5.9)	5.9 (5.3 - 6.8)	<0.001
Plasma renin activity, ng/mL/hour	0.4 (0.2 - 0.6)	0.9 (0.5 - 2.1)	<0.001
Plasma aldosterone concentration, pg/mL	212.5 (153.0 – 293.8)	102.0 (63.6 – 150.0)	<0.001
Comorbidities			
Diabetes, n (%)	29 (16.5)	197 (47.1)	<0.001
Dyslipidemia, n (%)	99 (56.3)	284 (67.9)	0.009
Anti-hypertensive drugs			
Calcium channel blocker, n (%)	108 (71.5)	262 (68.8)	0.604
α blocker, n (%)	12 (7.9)	31 (8.1)	1.000

Diuretic agent, n (%)	18 (11.9)	34 (8.9)	0.375
Sleep apnea			
AHI, n (%)	10.0 (4.8-20.3)	9.7 (3.9-19.6)	0.281
Normal (<5), n (%)	47 (26.7)	125 (29.9)	0.493
Mild (5 to <15), n (%)	68 (38.6)	145 (34.7)	0.411
Moderate (15 to <30), n (%)	33 (18.8)	104 (24.9)	0.130
Severe (AHI ≥30), n (%)	28 (15.9)	44 (10.5)	0.090

Data are presented as the mean ± standard deviation or median (25th-75th percentile) for continuous variables or number (%) for categorical dichotomous variables. P values based on the two-sample Welch's t-test or Mann-Whitney U-test are shown for comparisons of location parameters, such as the mean or median of two groups, or P values based on the Fisher's exact test for comparisons of percentage between groups. PA, primary aldosteronism; BP, blood pressure; LDL, low density lipoprotein; HDL, high density lipoprotein; eGFR, estimated glomerular filtration rate; AHI, apnea-hypopnea index

Table 2. Comparisons of baseline clinical characteristics among subjects divided based on degree of sleep apnea

Variables	Normal (AHI <5)	Mild (AHI 5 to <15)	Moderate (AHI 15 to <30)	Severe (AHI ≥30)	P value (Normal vs. Mild)	P value (Normal vs. Moderate)	P value (Normal vs. Severe)
Number	170	214	138	72	-	-	-
Age, years	59.3 ± 14.0	62.2 ± 11.7	64.9 ± 11.4	60.6 ± 13.8	0.026	<0.001	0.489
Male, n (%)	74 (43.5)	117 (54.7)	81 (58.7)	43 (59.7)	0.039	0.011	0.031
Body mass index, kg/m ²	22.9 ± 3.6	25.1 ± 4.7	26.1 ± 4.8	30.1 ± 6.4	<0.001	<0.001	<0.001
Current smoker, n (%)	37 (21.8)	59 (27.6)	34 (24.6)	24 (33.3)	0.235	0.646	0.083
Systolic BP, mmHg	130.2 ± 14.5	133.6 ± 15.3	133.6 ± 15.3	136.4 ± 14.3	0.024	0.045	0.002
Diastolic BP, mmHg	77.6 ± 10.1	78.9 ± 9.6	77.6 ± 9.5	78.7 ± 10.2	0.221	0.990	0.458
LDL cholesterol, mg/dL	112.8 ± 33.4	110.0 ± 31.5	113.2 ± 28.8	114.2 ± 32.5	0.540	0.930	0.798
HDL cholesterol, mg/dL	55.5 ± 18.0	54.9 ± 16.0	51.0 ± 15.1	50.3 ± 17.3	0.709	0.021	0.039
Triacylglycerol, mg/dL	102 (78 - 147)	115 (84 - 154)	125 (96 - 179)	141 (106 - 194)	0.203	0.002	<0.001
eGFR, mL/min/1.73m ²	83.0 ± 21.9	78.5 ± 21.8	75.6 ± 20.4	72.1 ± 23.6	0.043	0.002	<0.001
Fasting plasma glucose, mg/dL	97 (90 - 105)	101 (93 - 116)	104 (94 - 126)	103 (95 - 118)	0.001	<0.001	<0.001
HbA1c (%)	5.4 (5.1 - 6.0)	5.7 (5.3 - 6.6)	5.9 (5.4 - 6.8)	6.0 (5.6 - 6.8)	<0.001	<0.001	<0.001
Plasma renin activity, ng/mL/hr	0.7 (0.4 - 1.6)	0.6 (0.3 - 1.2)	0.8 (0.4 - 2.1)	0.8 (0.4 -1.7)	0.234	0.222	0.595
Plasma aldosterone concentration, pg/mL	127 (74 - 198)	121 (78 - 187)	125 (80 - 195)	147 (74 - 215)	0.812	0.662	0.718
Comorbidities							
Diabetes, n (%)	47 (27.6)	84 (39.3)	62 (44.9)	33 (45.8)	0.023	0.002	0.009

Dyslipidemia, n (%)	97 (57.1)	134 (62.6)	96 (70.0)	56 (77.8)	0.317	0.033	0.004
Anti-hypertensive drugs							
Calcium-channel blocker, n (%)	104 (68.9)	129 (67.2)	85 (69.1)	52 (78.8)	0.829	1.000	0.183
α blocker, n (%)	10 (6.6)	14 (7.3)	8 (6.5)	11 (16.7)	0.978	1.000	0.040
Diuretic agent, n (%)	8 (5.3)	23 (12.0)	14 (11.4)	7 (10.6)	0.051	0.105	0.260
Sleep apnea							
AHI	2.4 (1.1 - 3.6)	9.0 (7.1 - 11.5)	20.1 (16.7 - 24.2)	39.9 (33.0 - 45.6)	<0.001	<0.001	<0.001
PA, n (%)	45 (26.5)	69 (32.2)	34 (24.6)	28 (38.9)	0.264	0.814	0.077

Data are presented as the mean \pm standard deviation or median (25th-75th percentile) for continuous variables, or number (%) for categorical variables. P values based on the two-sample Welch's t-test or Mann-Whitney U-test are shown for comparisons of location parameters, such as mean or median of two groups, or P values based on the Fisher's exact test for comparisons of percentage between groups. PA, primary aldosteronism; EH, essential hypertension; AHI, apnea-hypopnea Index; BP, blood pressure; LDL, low density lipoprotein; HDL, high density lipoprotein; eGFR, estimated glomerular filtration rate

Table 3. Multivariable logistic regression analysis of factors associated with degree of sleep apnea

Variables	Mild (AHI 5 to <15)		Moderate (AHI 15 to <30)		Severe (AHI ≥30)	
	OR (95%CI)	P	OR (95%CI)	P	OR (95%CI)	P
Age, years (per 5)	1.02 (0.95 - 1.11)	0.560	1.18 (1.07 - 1.30)	0.001	1.13 (1.00 - 1.05)	0.084
Male	1.16 (0.82 - 1.63)	0.410	1.29 (0.87 - 1.91)	0.212	1.56 (0.88 - 2.78)	0.130
Body mass index, kg/m ² (per 5)	0.94 (0.78 - 1.13)	0.492	1.35 (1.1 - 1.65)	0.004	2.78 (2.08 – 3.73)	<0.001
Systolic BP, mmHg (per 10)	1.03 (0.92 - 1.16)	0.615	1.04 (0.91 - 1.19)	0.566	1.11 (0.92 – 1.34)	0.275
HbA1c (%)	1.05 (0.92 - 1.20)	0.485	1.08 (0.93 - 1.25)	0.335	1.16 (0.94 - 1.43)	0.174
eGFR, mL/min/1.73 m ² (per 5)	1.00 (0.97 - 1.05)	0.708	1.00 (0.95 - 1.05)	0.897	0.93 (0.86 – 1.00)	0.045
PA (vs. non-PA)	1.28 (0.86 - 1.90)	0.229	0.97 (0.60 - 1.57)	0.905	2.08 (1.09 – 3.95)	0.025

PA, primary aldosteronism; BP, blood pressure; eGFR, estimated glomerular filtration rate; OR, odds ratio; CI, confidence interval

**Subjects enrolled in HSCAA study (2010/10-2020/11) (n=1151)
Out of these, subjects with hypertensive including PA (n=781)**


**Excluded (n=128)
With autonomous cortisol secretion, pheochromocytoma,
primary hyperparathyroidism, eGFR<15 mL/min/1.73m², or dialysis treatment**

Missing baseline data (n=59)

**First analysis including subjects evaluated for sleep apnea
(total = 594, PA = 176, non-PA = 418)**

**Excluded (n=551)
Non-PA or no reevaluated**

Final analysis including subjects with PA re-evaluated for sleep apnea and renin activity (total = 45)



● $\Delta\text{AHI}(\text{post-pre})$, amount of change — 95% prediction ellipse